Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model
Chin Med J (Engl)
.
2023 Jan 5;136(1):102-104.
doi: 10.1097/CM9.0000000000002520.
Authors
Sanbao Chai
1
,
Shuqing Yu
2
,
Fengqi Liu
2
,
Zuoxiang Liu
2
,
Qingqing Yang
2
,
Feng Sun
2
Affiliations
1
Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China.
2
Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing 100191, China.
PMID:
36723862
PMCID:
PMC10106192
DOI:
10.1097/CM9.0000000000002520
No abstract available
MeSH terms
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Incretins* / therapeutic use
Risk Assessment
Substances
Incretins
Hypoglycemic Agents